A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

• Status: Recruiting
• Trial end date: 2026-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Have a diagnosis of HS for at least 12 months.

• Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III.

• Have an (abscess plus inflammatory nodule) count of at least 5.

• Agree to use topical antiseptics daily.

• Had an inadequate response or intolerance to a 28-day course of oral antibiotics.

Exclusion Criteria:

• Have more than 20 draining fistulae.

• Have had surgical treatment for HS in the last 4 weeks before randomization.

• Have an active skin disease or condition, that could interfere with the assessment of HS.

• Have a current or recent acute, active infection.

• Are immunocompromised.

• Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.